Two Sigma Investments LP Has $2.03 Million Stock Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Two Sigma Investments LP cut its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 65.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 70,823 shares of the specialty pharmaceutical company's stock after selling 135,582 shares during the quarter. Two Sigma Investments LP owned 0.22% of Collegium Pharmaceutical worth $2,029,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. MetLife Investment Management LLC grew its holdings in shares of Collegium Pharmaceutical by 8.5% during the 4th quarter. MetLife Investment Management LLC now owns 19,987 shares of the specialty pharmaceutical company's stock valued at $573,000 after purchasing an additional 1,558 shares during the last quarter. Barclays PLC grew its holdings in shares of Collegium Pharmaceutical by 152.2% during the 3rd quarter. Barclays PLC now owns 75,052 shares of the specialty pharmaceutical company's stock valued at $2,899,000 after purchasing an additional 45,291 shares during the last quarter. Millennium Management LLC grew its holdings in shares of Collegium Pharmaceutical by 38.8% during the 4th quarter. Millennium Management LLC now owns 185,918 shares of the specialty pharmaceutical company's stock valued at $5,327,000 after purchasing an additional 51,972 shares during the last quarter. Sanctuary Advisors LLC grew its holdings in shares of Collegium Pharmaceutical by 5.3% during the 4th quarter. Sanctuary Advisors LLC now owns 18,928 shares of the specialty pharmaceutical company's stock valued at $542,000 after purchasing an additional 952 shares during the last quarter. Finally, Amundi grew its holdings in shares of Collegium Pharmaceutical by 188.3% during the 4th quarter. Amundi now owns 15,568 shares of the specialty pharmaceutical company's stock valued at $446,000 after purchasing an additional 10,168 shares during the last quarter.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on COLL. Needham & Company LLC reaffirmed a "buy" rating and set a $46.00 price target on shares of Collegium Pharmaceutical in a report on Wednesday, April 9th. Piper Sandler restated a "neutral" rating and issued a $37.00 price target (up from $36.00) on shares of Collegium Pharmaceutical in a research report on Friday, May 9th. Wall Street Zen cut shares of Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research report on Saturday, April 19th. Finally, HC Wainwright restated a "buy" rating and issued a $50.00 price target on shares of Collegium Pharmaceutical in a research report on Monday, March 24th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, Collegium Pharmaceutical presently has a consensus rating of "Moderate Buy" and a consensus target price of $43.80.

Insider Buying and Selling

In related news, EVP Scott Dreyer sold 2,255 shares of the stock in a transaction on Friday, March 14th. The shares were sold at an average price of $30.00, for a total transaction of $67,650.00. Following the transaction, the executive vice president now directly owns 124,421 shares of the company's stock, valued at $3,732,630. This represents a 1.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Colleen Tupper sold 977 shares of the stock in a transaction on Friday, March 14th. The stock was sold at an average price of $30.00, for a total transaction of $29,310.00. Following the transaction, the chief financial officer now directly owns 164,269 shares in the company, valued at approximately $4,928,070. This represents a 0.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 13,677 shares of company stock valued at $410,414 over the last ninety days. 2.51% of the stock is owned by corporate insiders.

Collegium Pharmaceutical Trading Up 0.3%

NASDAQ COLL traded up $0.10 on Thursday, hitting $29.50. The company's stock had a trading volume of 159,175 shares, compared to its average volume of 418,351. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. Collegium Pharmaceutical, Inc. has a 1-year low of $23.23 and a 1-year high of $42.29. The company's 50-day moving average is $27.98 and its 200 day moving average is $29.59. The firm has a market cap of $947.89 million, a PE ratio of 12.72 and a beta of 0.63.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 earnings per share for the quarter, missing the consensus estimate of $1.50 by ($0.01). Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The firm had revenue of $177.76 million for the quarter, compared to analyst estimates of $174.96 million. During the same quarter last year, the company earned $1.45 earnings per share. The company's quarterly revenue was up 22.7% compared to the same quarter last year. As a group, analysts predict that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.